Sciforum’s Post

The Life Sciences Future50 report showcases how the UK can accelerate the development of one of its most important sectors; life sciences. As the last few years have shown the value these companies bring to our daily lives - let alone the £43 billion added to the UK economy - is extraordinary. And beyond their products is a whole chain of academic brilliance and depth of capabilities. Read more on the unique opportunity that the UK has to boost this sector into a true life sciences superpower. https://lnkd.in/eccaNi9k #lifesciences #pharmaceuticals #LifeSciencesFuture50

🌟 Reflections on the 2nd Global Research Lab 2023-2024🌟 A few months back, I had the privilege of participating in the 2nd Global Research Lab organized by Pharmacy Education under IPSF Pharmaceutical Sciences initiative🌐 🔍 Throughout the event, I delved into the intricate world of research. From understanding research design to data collection and analysis, I gained practical skills that will undoubtedly shape my future endeavors. 📊🔬 🙌 Sama Ghozlan ,the coordinator, and Kareem Arafat , pharmacy education Chairperson deserves a heartfelt shout-out for their unwavering dedication. Their guidance, along with insights from experienced speakers, demystified the research process. 🗣️📝 📝 The event also shed light on effective publication writing. I learned that clear, concise language and impactful communication are paramount in scientific papers. The speaker's tips on structuring research papers and presenting findings were pure gold. 💡📄 🔍 One of my key takeaways? Mastering search strings for literature reviews. Now, I can efficiently explore databases and critically evaluate relevant studies. 📚🔎 🌿 The emphasis on evidence-based practice resonated deeply with me. It reinforced the vital role research plays in pharmacy practice. 💊🌱 Overall, the event was an enlightening journey and I am thrilled to share my certificate from the 2nd Global Research Lab project. Regular assignments kept me on my toes, reinforcing my knowledge and understanding. 🧠📚 Thank you IPSF - International Pharmaceutical Students' Federation #ResearchMatters #PharmaceuticalSciencesInitiatives #PharmacyEducation #IPSF #ProfessionalDevelopment

Have you published a paper in the past three years that could have major 3Rs impacts, whether the 3Rs were a primary focus of your work or a secondary benefit? Wherever you are in the world, you can apply for the NC3Rs' International 3Rs Prize. This prestigious annual award, sponsored by GSK, consists of a £2k personal award and a £28k prize grant to further the 3Rs impact of the winning research. Researchers in any field of academia or industry are eligible. Visit https://lnkd.in/emst4F2U to find out more and apply by 1 May – or why not encourage a colleague to apply? #3Rs #AnimalResearch #ResearchAnimals

We’re pleased to announce that CIRS has published a new Research Agenda, which outlines our research priorities for 2024-2026 as well as plans for our regulatory and HTA workstreams for 2024. CIRS generated its 2024-2026 research plan with significant input from its Scientific Advisory Council and HTA Steering Committee. Priority areas were identified and fleshed out through meetings of Topic Groups in 2022-2023, which focused on patient engagement, expedited pathways and metrics. Feedback from these groups, careful review of the landscape as well as conversations with various CIRS member companies, agencies and other stakeholders, were reviewed and organised into three main research themes (below). This research plan will be achieved through research projects, workshops and other meetings. We hope this Research Agenda resonates with our stakeholders - thank you to everyone who has helped in its development! #RegulatoryScience #HTA #RegulatoryAffairs #HEOR #pharmaceuticals

The #ECRAIDPrime consortium has received full regulatory approvals to open the #adaptiveplatformtrial in Belgium and Germany. At the project's General Assembly last month, Principal Investigator Chris Butler shared, "The excitement was palpable, bringing us together as a group. We’re now looking forward to receiving approvals in more countries, allowing us to begin our trial across all seven countries, with hopefully more to come." Read more 👉🏾 https://lnkd.in/ek3Kuk-A #europeancommission #primarycare #COVID19 #pandemicpreparedness University of Oxford Nuffield Department of Primary Care Health Sciences - University of Oxford UMC Utrecht Norwegian Institute of Public Health ECRIN (European Clinical Research Infrastructure Network) University of Antwerp Laboratory of Medical Microbiology Alike W. van der Velden Frank Leus Aida Salcic Claire-Marie Martis Ilse Rietveld Victoria C. Simensen Jacques Demotes Mainard #clinicaltrials #clinicalresearch

If you are interested in learning about Drug Discovery, you might find this useful. I will be attending this session for sure!

ChE peeps - Free seminar on the Drug Development process and their Graduate Certificate: Drug Development: From Discovery to Commercialization

Almost forgot to post this brilliant report that my very own pharma team at PwC has prepared recently. It explores the UK's potential for becoming a global life sciences powerhouse (which obviously is the goal) and provides a list of 50 exciting companies, which we think will be the drivers of that growth due to their technology, innovative business models and ideas. There is a smart methodology behind the sampling, infographics, maps - all the things I like 🤗 #pharmaceutical #pwc https://pwc.to/47c72I0

The 2023 PwC UK’s 'Life Sciences Future 50' report is now out and we are delighted to be have been selected as one of the UK’s most promising companies #lifesciences sector. The report shines a light on the world-class science and innovation in the UK, including in #Scotland to deliver breakthroughs in human healthcare and new medicines. As a clinical-stage company, the report highlights how Kynos Therapeutics is a developing an innovative portfolio of first-in-class medicines. Our molecules block the action of #KMO - a key enzyme at the interface of inflammation, immunity and metabolism. Our initial focus is on preventing tissue and organ damage during acute inflammation in conditions such as acute kidney injury and acute pancreatitis where no specific therapies are currently approved. Read the report: https://lnkd.in/eByPr9Q5 Learn more about our vision: www.kynostx.com/ #BioTech #DrugDiscovery #lifesciences #innovation

Some insights into the upcoming life sciences industry and market